<?xml version="1.0" encoding="UTF-8"?>
<ref id="B141">
 <label>141.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lutz</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Lazzaro</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Habbeddine</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Schmidt</surname>
    <given-names>KE</given-names>
   </name>
   <name>
    <surname>Baumhof</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Mui</surname>
    <given-names>BL</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines</article-title>. 
  <source>NPJ Vaccines</source> (
  <year>2017</year>) 
  <volume>2</volume>:
  <fpage>29</fpage>. 
  <pub-id pub-id-type="doi">10.1038/s41541-017-0032-6</pub-id>
  <?supplied-pmid 29263884?>
  <pub-id pub-id-type="pmid">29263884</pub-id>
 </mixed-citation>
</ref>
